Clinical Trial Results, New Products, Employee Grants, Pricing of Offering - Research Report on GSK, Intuitive, IDEXX, Sanofi, and Foundation Medicine Editor Note: For more information about this release, please scroll to bottom. PR Newswire NEW YORK, November 19, 2013 NEW YORK, November 19, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting GlaxoSmithKline plc (NYSE: GSK), Intuitive Surgical, Inc. (NASDAQ: ISRG), IDEXX Laboratories, Inc. (NASDAQ: IDXX), Sanofi SA (NYSE: SNY), and Foundation Medicine, Inc. (NASDAQ: FMI). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. GlaxoSmithKline plc Research Report On November 12, 2013, GlaxoSmithKline plc (GSK) announced top-line results from its Phase III STABILITY trial, which evaluated the efficacy of its investigational Lp-PLA2 inhibitor darapladib in adults with chronic coronary heart disease (CHD). According to GSK, the study did not meet the primary endpoint measure, which was time to first occurrence of any major adverse cardiovascular event from the composite of myocardial infarction (heart attack), stroke, and cardiovascular death (relative risk reduction of 6%; p=0.199), however there were greater reductions (nominal p<=0.05) in some of the pre-defined secondary endpoints that require further analysis. The Company informed that in the trial the overall safety profile did not demonstrate major imbalance in serious adverse events between the active and placebo groups. GSK stated that further analysis of the data is ongoing and the Company will submit the full results of the STABILITY study for presentation at a scientific meeting in to be held in 2014. According to GSK, darapladib is not approved for use anywhere in the world. The Full Research Report on GlaxoSmithKline plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/2a35_GSK -- Intuitive Surgical, Inc. Research Report On November 8, 2013, Intuitive Surgical, Inc. (Intuitive) reported that that the equity awards, which were approved by the Compensation Committee of the Board of Directors, were granted to 22 new employees. According to the Company, the awards were granted under the Company's 2009 Commencement Incentive Plan, pursuant to NASDAQ Marketplace Rule 5635(c) (4). The Company stated that the awards granted the 22 employees, options to purchase an aggregate of 6,605 shares of Intuitive's common stock at an exercise price of $379.58 per share. Intuitive stated that the options vest over four years will expire in 10 years, assuming continued employment. The Full Research Report on Intuitive Surgical, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/5f98_ISRG -- IDEXX Laboratories, Inc. Research Report On November 14, 2013, IDEXX Laboratories, Inc. (IDEXX) reported that it has introduced the SNAP Pro Mobile Device, and has started taking pre-orders for the product in North America while shipment of the same is anticipated by late Q1 2014. According to the Company, SNAP Pro Mobile Device is the latest innovation in rapid point-of-care diagnostic testing. IDEXX stated that the core feature of the stated device includes - fast and easy to use, improves staff efficiency and saves practices money and Populates VetConnect PLUS with additional diagnostic results. Dana Belisle, Vice President and General Manager of IDEXX Rapid Assay said, "The immediate, accurate results provided by SNAP tests are an essential part of everyday diagnostic protocols for tens of thousands of practices worldwide. Adding the SNAP Pro Mobile Device to established protocols significantly improves practice efficiency by automating the entire SNAP test process." The Full Research Report on IDEXX Laboratories, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/bf62_IDXX -- Sanofi SA Research Report On November 7, 2013, Sanofi SA (Sanofi) announced that it has priced its offering of €1 billion of notes, due by 2023, bearing interest at an annual rate of 2.50%. The Company informed that the issue is drawn under the Company's Euro Medium Term Note Programme and it plans to use the proceeds of the offering for general corporate purposes, including payment of existing borrowings. The Full Research Report on Sanofi SA - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/29ea_SNY -- Foundation Medicine, Inc. Research Report On November 8, 2013, Foundation Medicine, Inc. (Foundation Medicine) announced that it will present new clinical data featuring its second clinical product, a fully informative genomic profile for hematologic malignancies, which was developed in collaboration with Memorial Sloan-Kettering Cancer Center, at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition. Foundation Medicine stated that the event is scheduled to take place from December 7, 2013 through December 10, 2013 in New Orleans. Vincent Miller, M.D., Chief Medical Officer of Foundation Medicine said, "We are making progress toward the introduction of our second clinical product, FoundationOne Heme, by early 2014 and look forward to sharing initial data with the hematology community at this year's ASH meeting. We are building on our comprehensive next-generation sequencing platform to offer a fully informative genomic profile with clinically actionable information for oncologists and patients with hematologic malignancies. We believe these findings will advance patient care for blood based cancers." The Full Research Report on Foundation Medicine, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/d9a0_FMI ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. AnalystsCorner.com SOURCE Analysts' Corner Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
Clinical Trial Results, New Products, Employee Grants, Pricing of Offering - Research Report on GSK, Intuitive, IDEXX, Sanofi,
Press spacebar to pause and continue. Press esc to stop.